In the #PROSERA phase 3 study, #Seralutinib demonstrated a placebo-adjusted increase of 13.3 m in the 6-minute walk distance, with more pronounced improvements observed in high-risk subgroups.
Learn more: https://bit.ly/4lb32Qd
#RareDisease #PAH #PulmonaryArterialHypertension #PAH
1
0
0
0